vs
Side-by-side financial comparison of Inuvo, Inc. (INUV) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Inuvo, Inc. is the larger business by last-quarter revenue ($14.3M vs $12.6M, roughly 1.1× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -4.2%, a 254.8% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -45.6%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs -8.5%).
Inuvo, Inc. is a digital marketing technology firm that develops AI-powered advertising solutions. It offers intent-based audience targeting, performance marketing, and brand awareness services for retail, finance, and consumer goods clients, mainly operating across the North American market.
INUV vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.3M | $12.6M |
| Net Profit | $-593.9K | $31.5M |
| Gross Margin | 66.4% | — |
| Operating Margin | -8.5% | — |
| Net Margin | -4.2% | 250.7% |
| Revenue YoY | -45.6% | 24080.8% |
| Net Profit YoY | -520.2% | 250.9% |
| EPS (diluted) | — | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $14.3M | $12.6M | ||
| Q3 25 | $22.6M | $0 | ||
| Q2 25 | $22.7M | $0 | ||
| Q1 25 | $26.7M | $12.0K | ||
| Q4 24 | $26.2M | $52.0K | ||
| Q3 24 | $22.4M | $65.0K | ||
| Q2 24 | $18.2M | $114.0K | ||
| Q1 24 | $17.0M | $140.0K |
| Q4 25 | $-593.9K | $31.5M | ||
| Q3 25 | $-1.7M | $-7.4M | ||
| Q2 25 | $-1.5M | $-1.7M | ||
| Q1 25 | $-1.3M | $-13.9M | ||
| Q4 24 | $141.3K | — | ||
| Q3 24 | $-2.0M | $-17.1M | ||
| Q2 24 | $-1.7M | $-17.9M | ||
| Q1 24 | $-2.1M | $-12.7M |
| Q4 25 | 66.4% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 75.4% | — | ||
| Q1 25 | 79.0% | — | ||
| Q4 24 | 83.1% | — | ||
| Q3 24 | 88.4% | — | ||
| Q2 24 | 84.0% | — | ||
| Q1 24 | 87.7% | — |
| Q4 25 | -8.5% | — | ||
| Q3 25 | -7.4% | — | ||
| Q2 25 | -9.0% | — | ||
| Q1 25 | -6.6% | -122758.3% | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | -8.7% | -28604.6% | ||
| Q2 24 | -9.3% | -16720.2% | ||
| Q1 24 | -12.3% | -9987.1% |
| Q4 25 | -4.2% | 250.7% | ||
| Q3 25 | -7.7% | — | ||
| Q2 25 | -6.6% | — | ||
| Q1 25 | -4.7% | -115550.0% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | -9.1% | -26380.0% | ||
| Q2 24 | -9.6% | -15668.4% | ||
| Q1 24 | -12.4% | -9049.3% |
| Q4 25 | — | $0.56 | ||
| Q3 25 | $-0.12 | $-0.13 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | $-0.01 | $-0.25 | ||
| Q4 24 | $0.14 | — | ||
| Q3 24 | $-0.15 | $-0.32 | ||
| Q2 24 | $-0.01 | $-0.33 | ||
| Q1 24 | $-0.02 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $10.0M | $59.0M |
| Total Assets | $24.9M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.3M | ||
| Q3 25 | — | $48.6M | ||
| Q2 25 | — | $31.2M | ||
| Q1 25 | — | $48.9M | ||
| Q4 24 | — | $52.9M | ||
| Q3 24 | — | $76.3M | ||
| Q2 24 | $2.0M | $63.5M | ||
| Q1 24 | $2.0M | $82.3M |
| Q4 25 | $10.0M | $59.0M | ||
| Q3 25 | $10.4M | $26.5M | ||
| Q2 25 | $12.1M | $32.8M | ||
| Q1 25 | $13.4M | $33.8M | ||
| Q4 24 | $13.5M | $46.1M | ||
| Q3 24 | $12.4M | $65.5M | ||
| Q2 24 | $13.5M | $80.5M | ||
| Q1 24 | $15.1M | $96.2M |
| Q4 25 | $24.9M | $68.9M | ||
| Q3 25 | $29.9M | $54.2M | ||
| Q2 25 | $28.7M | $62.1M | ||
| Q1 25 | $31.7M | $77.7M | ||
| Q4 24 | $32.2M | $110.5M | ||
| Q3 24 | $29.0M | $135.2M | ||
| Q2 24 | $28.5M | $149.9M | ||
| Q1 24 | $29.8M | $167.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.0K | $-8.4M |
| Free Cash FlowOCF − Capex | $-339.9K | — |
| FCF MarginFCF / Revenue | -2.4% | — |
| Capex IntensityCapex / Revenue | 2.5% | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | $-3.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.0K | $-8.4M | ||
| Q3 25 | $-1.6M | $17.4M | ||
| Q2 25 | $143.7K | $-17.7M | ||
| Q1 25 | $-366.9K | $-4.0M | ||
| Q4 24 | $329.9K | $-23.4M | ||
| Q3 24 | $1.1M | $12.8M | ||
| Q2 24 | $195.4K | $-18.7M | ||
| Q1 24 | $-1.4M | $5.9M |
| Q4 25 | $-339.9K | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-263.1K | — | ||
| Q1 25 | $-818.6K | — | ||
| Q4 24 | $-117.7K | — | ||
| Q3 24 | $584.0K | — | ||
| Q2 24 | $-266.3K | — | ||
| Q1 24 | $-1.8M | — |
| Q4 25 | -2.4% | — | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -1.2% | — | ||
| Q1 25 | -3.1% | — | ||
| Q4 24 | -0.4% | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | -1.5% | — | ||
| Q1 24 | -10.7% | — |
| Q4 25 | 2.5% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 2.8% | — |
| Q4 25 | — | -0.26× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
